Skip to main content

Advertisement

Log in

Urinary Disturbance after Therapy for Cervical Cancer: Urodynamic Evaluation and β2-Agonist Medication

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract:

Urinary disturbance frequently develops following therapy for cervical cancer; however, no effective medical treatment has so far been reported. Sixty-five patients who developed urinary disturbance after radiation therapy, radical hysterectomy or radical hysterectomy with radiation therapy for cervical cancer underwent urodynamic assessment. Those who underwent radical hysterectomy with radiation therapy experienced the most severe urine loss, as determined by the pad test. All patients showed markedly reduced bladder compliance. A β2-agonist (mabuterol) significantly improved compliance, bladder capacity and flow rate. It is suggested that medication with mabuterol is a potential novel approach to the treatment of urinary disturbance after therapy for cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamada, K., Kihana, T., Kataoka, M. et al. Urinary Disturbance after Therapy for Cervical Cancer: Urodynamic Evaluation and β2-Agonist Medication. Int Urogynecol J 10, 365–370 (1999). https://doi.org/10.1007/s001920050061

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s001920050061

Navigation